Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05116956
Other study ID # 1-0_30042021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 8, 2021
Est. completion date July 22, 2023

Study information

Verified date November 2021
Source Henri Mondor University Hospital
Contact Nicolas de Prost, MD, PhD
Phone +33145178617
Email nicolasdeprost@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Necrotizing soft-tissue infections (NSTI) are rare and life-threatening bacterial infections characterized by subcutaneous tissue, fascia or muscle necrosis. Few prospective studies have been performed and our current knowledge on NSTI is mostly derived from retrospective single center studies. The "SKin and soft tissue necrotizing INfections in the ICU" (SKIN-ICU) study is a multinational prospective non-interventional cohort study that will include patients admitted to the ICU/intermediate care unit for NSTI or not. The objectives of the study are : 1. To assess hospital (i.e., ICU and hospital mortality) and medium-term (day-90 mortality, functional outcomes and health-related quality of life scores, HR-QoL) outcomes 2. To report the clinical presentation and microbiological epidemiology of NSTI and identify independent prognostic factors of mortality and altered quality of life


Description:

Necrotizing soft-tissue infections (NSTI) are rare and life-threatening bacterial infections characterized by subcutaneous tissue, fascia or muscle necrosis. The mortality of NSTIs is high, ranging from 9% in non-selected patients to up to 30% in the most severe forms requiring intensive care unit (ICU) admission . With an incidence of 4/100 000 persons per year, initial misdiagnosis is frequent, with no reliable diagnostic test available, frequently leading to a delayed surgical debridement of infected tissues, one of the main modifiable prognostic factors. According to international recommendations, any cutaneous infection associated with the failure of one or more organs or showing a dramatic deterioration must include the diagnosis of NSTI for consideration, even if there is no local sign of the condition being severe. The diagnosis is confirmed by identifying during surgery deficient tissue, sometimes necrotic, which comes away easily in the fingers and by the presence of the typical, foul-smelling "dishwasher" exudate. The early management of NSTIs is challenging and requires a coordinated and multidisciplinary approach. Treatment of NSTIs consists of early broad-spectrum antimicrobial therapy together with emergency and aggressive surgical debridement including excision of all necrotic and infected tissues. Few prospective studies have been performed and our current knowledge on NSTI is mostly derived from retrospective single center studies.The few randomized therapeutic trials testing interventions in this setting have been disappointing, in part because of the difficulty to identify subgroups for individualized treatments. A large international study aimed at collecting granular data on the clinical presentation, microbiology, management and outcomes of patients with NSTI admitted in the ICU and involving a large number of centers and countries is thus desirable to improve our knowledge on this devastating condition. The "SKin and soft tissue INfections in the ICU" (SKIN-ICU) study is a multinational prospective non-interventional cohort study that will include patients with NSTI admitted or not to the ICU/intermediate care unit and aim at addressing the following points: 1) Hospital (i.e., ICU and hospital mortality) and medium-term outcomes (three- and six-month survival, functional outcomes and health-related quality of life scores, HR-QoL); and 2) Clinical presentation and microbiological epidemiology of NSTI.


Recruitment information / eligibility

Status Recruiting
Enrollment 1033
Est. completion date July 22, 2023
Est. primary completion date July 22, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Patient with surgically-confirmed NSTI (i.e., macroscopic appearance of tissue during surgery revealing swollen, dull gray tissues with a thin, brownish exudate with or without necrosis) Exclusion Criteria: - Patient deprived of liberty by judicial or administrative decision or patient under guardianship - Expressed opposition to project's participation at the project

Study Design


Intervention

Other:
non interventional
Multinational prospective, standard care data collection, non-interventional, study not involving human subjects

Locations

Country Name City State
France Hopital Henri Mondor Créteil

Sponsors (2)

Lead Sponsor Collaborator
Henri Mondor University Hospital European Society of Intensive Care Medicine

Country where clinical trial is conducted

France, 

References & Publications (5)

Madsen MB, Skrede S, Bruun T, Arnell P, Rosén A, Nekludov M, Karlsson Y, Bergey F, Saccenti E, Martins Dos Santos VAP, Perner A, Norrby-Teglund A, Hyldegaard O. Necrotizing soft tissue infections - a multicentre, prospective observational study (INFECT): protocol and statistical analysis plan. Acta Anaesthesiol Scand. 2018 Feb;62(2):272-279. doi: 10.1111/aas.13024. Epub 2017 Oct 29. — View Citation

Peetermans M, de Prost N, Eckmann C, Norrby-Teglund A, Skrede S, De Waele JJ. Necrotizing skin and soft-tissue infections in the intensive care unit. Clin Microbiol Infect. 2020 Jan;26(1):8-17. doi: 10.1016/j.cmi.2019.06.031. Epub 2019 Jul 5. Review. — View Citation

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15;59(2):147-59. doi: 10.1093/cid/ciu296. Epub 2014 Jun 18. — View Citation

Stevens DL, Bryant AE. Necrotizing Soft-Tissue Infections. N Engl J Med. 2017 Dec 7;377(23):2253-2265. doi: 10.1056/NEJMra1600673. Review. — View Citation

Urbina T, Canoui-Poitrine F, Hua C, Layese R, Alves A, Ouedraogo R, Bosc R, Sbidian E, Chosidow O, Dessap AM, de Prost N; Henri Mondor Hospital Necrotizing Fasciitis Group. Long-term quality of life in necrotizing soft-tissue infection survivors: a monocentric prospective cohort study. Ann Intensive Care. 2021 Jul 2;11(1):102. doi: 10.1186/s13613-021-00891-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary mortality day 90
Secondary Functional outcome Activity of daily living (ADL, 6 questions on selfcare, household, employment, shopping, travel, and communication, each rated 0 (best performance), 1 or 2 (worst performance). An ADL score of 12 indicates a high level of dependence. day 90
Secondary Health-related quality of life outcome EuroQol five-dimensional descriptive system (EQ-5D-5L score). It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 3 response categories corresponding to no problems, some problems, and extreme problems. The instrument is designed for self-completion, and respondents also rate their overall health on the day of the interview on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). day 90
Secondary Microbiology Microorganisms involved in blood cultures and per operative tissue samples (species, antibiogram, resistance and "difficult to treat" status) During the first 72 hours of hospital admission
Secondary Skin grafting and amputation Skin grafting and limb amputation performed within three months of hospital admission will be recorded At day 90
Secondary SAPS II score The Simplified Acute Physiology Score II (SAPS II) is a severity of disease score, which is associated with the probability of death at intensive care unit admission (the greater the value of the SAPS II, the greater the odd of death increases). Within 24 hours of hospital admission
Secondary SOFA score The Sequential Organ Failure Assessment score is a severity of illness score used in sepsis.the greater the value of the SOFA, the greater the odd of death increases Within 24 hours of hospital admission
Secondary Anatomic location Llimbs upper or lower, abdomino-perineal, neck/head, periarticular/circonferential involvement Within 24 hours of hospital admission
Secondary Body surface area involved Quantified with the Wallace rule of nine Within 24 hours of hospital admission
Secondary Portal of entry of the NSTI Portal of entry of the NSTI will be recorder (e.g., skin ulcer, trauma, other) Within 24 hours of hospital admission
See also
  Status Clinical Trial Phase
Terminated NCT05157360 - HAT for the Treatment of Sepsis Associated With NASTI Phase 1/Phase 2
Recruiting NCT04801615 - Characteristics of Patients With Necrotizing Soft Tissue Infections
Withdrawn NCT02314468 - Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation N/A
Terminated NCT03403751 - Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury Phase 3
Active, not recruiting NCT03482245 - The Role of Circadian Clock Proteins in Innate and Adaptive Immunity N/A
Terminated NCT05032625 - To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
Recruiting NCT05243966 - Myriad™ Augmented Soft Tissue Reconstruction Registry
Active, not recruiting NCT06126263 - Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Completed NCT02501382 - Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Completed NCT02180906 - Biomarkers in Patients With Flesh-eating Bacterial Infections N/A
Completed NCT03147352 - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Recruiting NCT06002607 - Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Completed NCT02111161 - Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Phase 2